ZS Pharma & AstraZeneca v. Ascent & Hetero: LOKELMA Patent Consent Judgment
ZS Pharma and AstraZeneca filed suit in the Delaware District Court against Ascent Pharmaceuticals and Hetero Drugs, asserting 13 patents covering LOKELMA® (sodium zirconium cyclosilicate) oral suspension. The case resolved via a consent judgment after 799 days — a resolution mechanism that typically signals a negotiated agreement rather than a contested merits ruling.
13-Patent LOKELMA Enforcement Ends in Consent Judgment After 799 Days
On 22 August 2022, ZS Pharma, Inc. and AstraZeneca Pharmaceuticals LP filed an infringement action in the U.S. District Court for the District of Delaware (Case No. 1:22-cv-01099) before Judge Jennifer L. Hall. The plaintiffs asserted 13 U.S. patents covering LOKELMA® — sodium zirconium cyclosilicate for oral suspension in 5 g and 10 g per-packet doses — against Ascent Pharmaceuticals, Inc. and Hetero Drugs, Ltd. The breadth of the patent portfolio, spanning composition, formulation, and method-of-use claims, is consistent with a Hatch-Waxman ANDA litigation strategy designed to protect market exclusivity.
The case closed on 29 October 2024 via a consent judgment — a court-entered disposition agreed to by all parties. This mechanism typically signals that the defendants either agreed to be bound by specified terms (such as a market entry date or licensing arrangement) or conceded infringement as part of a negotiated resolution. Unlike a default judgment, a consent judgment reflects mutual agreement and is immediately enforceable. The public record does not disclose the specific commercial terms underlying the parties’ agreement.
At 799 days, the case duration is notable for a consent judgment resolution, suggesting substantive negotiation occurred well into the litigation lifecycle. The involvement of two defendants — a U.S. generic manufacturer and an Indian API/drug company — alongside a 13-patent assertion portfolio suggests plaintiffs pursued a comprehensive blocking strategy. What remains unknown from the public record is whether the consent judgment includes market entry restrictions, royalty arrangements, or an agreed infringement finding, which would materially affect the competitive landscape for generic sodium zirconium cyclosilicate products.
Filing to Consent Judgment in 799 days
799 days — above the median for ANDA/Hatch-Waxman patent cases in Delaware
Consent judgment entered: what the resolution means for both parties
What a consent judgment means in Hatch-Waxman litigation
A consent judgment is a court-entered order agreed to by all parties, combining the finality of a court ruling with the flexibility of a negotiated settlement. In Hatch-Waxman ANDA litigation, consent judgments often include agreed findings of infringement, validity, or market entry dates. The judgment is immediately enforceable and typically resolves the 30-month stay mechanism. The underlying commercial terms are generally not disclosed in the public docket.
Negotiated court orderAstraZeneca and ZS Pharma secure enforceable judgment
A consent judgment entered in plaintiffs’ favour — or on agreed terms — provides AstraZeneca and ZS Pharma with an enforceable court order protecting LOKELMA’s market position. If the judgment includes an agreed-upon market entry date, it effectively preserves exclusivity for a defined period. The 13-patent portfolio asserted suggests plaintiffs sought layered protection across composition, formulation, and method-of-use dimensions, which a consent judgment can preserve in totality.
Exclusivity likely preservedAscent and Hetero bound by court-entered terms
Ascent Pharmaceuticals and Hetero Drugs are bound by the consent judgment’s terms, which may restrict their ability to launch a generic sodium zirconium cyclosilicate product until specified conditions are met. A consent judgment also typically bars relitigation of the issues it resolves. Whether defendants retained any licensing rights or agreed future launch dates is not disclosed in the public record, but the resolution is consistent with a commercial compromise rather than an outright defeat.
Launch terms undisclosedLOKELMA generic entry timeline remains uncertain for the market
For the hyperkalemia treatment market, the consent judgment’s undisclosed terms create uncertainty about when a generic sodium zirconium cyclosilicate product may enter. Other ANDA filers and potential generic entrants face a strengthened enforcement signal — AstraZeneca and ZS Pharma demonstrated willingness to assert the full 13-patent portfolio and litigate for over two years. Companies developing competing formulations should assess FTO exposure across all 13 asserted patents before advancing clinical or commercial programmes.
Market entry date undisclosedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ZS Pharma, Inc. | Company | Pharmaceutical IP holding and commercial entity — holder of US10398730B2 and 12 related LOKELMA patentsSearch in Eureka ↗ |
| Co-Plaintiff | Astrazeneca Pharmaceuticals, LP | Company | Search in Eureka ↗ |
| Defendant | Ascent Pharmaceuticals, Inc. | Company | Ascent Pharmaceuticals (U.S. generic manufacturer) and Hetero Drugs (Indian generic and API supplier)Search in Eureka ↗ |
| Co-Defendant | Hetero Drugs, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel O’boyle | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Gyuhyun (joanne) Bae | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Hassen Sayeed | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mark A. Hayden | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing ZS Pharma, Inc.Search in Eureka ↗ |
| Defendant counsel | Cortlan S. Hitch | Attorney | Counsel for Ascent Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Kenneth Laurence Dorsney | Attorney | Counsel for Ascent Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Mark A. Hayden | Attorney | Counsel for Ascent Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris James LLP | Law Firm | Representing Ascent Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The case terminated via a consent judgment — a court-entered order that all parties agreed to, giving it the binding force of a judicial ruling without a contested merits adjudication. In the ANDA/Hatch-Waxman context, consent judgments routinely incorporate agreed infringement or validity findings and may specify commercial launch dates. The phrasing ‘Consent Judgment’ as both the verdict and basis of termination is consistent with a fully negotiated resolution. The specific terms — including any market entry restrictions or licensing provisions — are not disclosed in the public case record.
US10398730B2 and 12 related patents — sodium zirconium cyclosilicate oral suspension
The 13 patents asserted in this case collectively cover LOKELMA® (sodium zirconium cyclosilicate), a selective potassium binder approved for the treatment of hyperkalemia. The patents span a range of claim types including compositions of matter, pharmaceutical formulations, and methods of treatment, with application filing dates ranging from 2013 through 2018. This layered filing strategy is characteristic of a pharmaceutical lifecycle management programme designed to extend effective exclusivity beyond any single patent’s expiry.
From a competitive intelligence perspective, the 13-patent portfolio creates a substantial clearance challenge for any generic or biosimilar entrant targeting sodium zirconium cyclosilicate. AstraZeneca’s acquisition of ZS Pharma in 2015 brought this portfolio under a major pharma enforcement umbrella, signalling sustained commercial commitment to protecting LOKELMA’s market position. The hyperkalemia treatment market — which also includes patiromer — is a growing specialty segment, making this IP estate strategically significant for both originator and generic players.
Should you run an FTO against the LOKELMA patent portfolio?
Any company developing, manufacturing, or commercialising sodium zirconium cyclosilicate — or related zirconium silicate potassium binders — should conduct a freedom-to-operate assessment against all 13 patents asserted in this case. This includes ANDA filers, API manufacturers, contract development and manufacturing organisations (CDMOs), and companies developing next-generation oral potassium binders. The consent judgment outcome confirms these patents are actively enforced and enforceable in U.S. courts.
PatSnap Eureka’s FTO Search Agent can map your compound or formulation against the claim scope of each of the 13 asserted patents, identify design-around opportunities, and flag related continuations or divisionals that may not yet be asserted. Eureka’s portfolio monitoring tools can also alert you to new filings from ZS Pharma or AstraZeneca that extend this estate — critical intelligence before filing an ANDA or advancing a competing potassium binder through clinical development.
Run a freedom-to-operate analysis on US10398730B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: sodium zirconium cyclosilicate & potassium binders
Explore related Hatch-Waxman infringement actions in the Delaware District Court involving oral suspension formulation patents and hyperkalemia treatment compounds.
What this case signals for the hyperkalemia treatment IP landscape
A 13-patent consent judgment in Delaware reinforces AstraZeneca’s LOKELMA enforcement posture and raises the bar for any generic entrant.
13-patent assertion creates a high clearance burden for generic filers
Asserting 13 patents in a single ANDA action is a deliberate portfolio strategy. Any ANDA filer targeting sodium zirconium cyclosilicate must now clear composition, formulation, and method-of-use claims simultaneously. A successful consent judgment outcome reinforces this as a viable and effective enforcement model for AstraZeneca going forward.
Consent judgment after 799 days suggests terms were commercially negotiated
Cases resolved by consent judgment after two-plus years of litigation typically reflect substantive commercial negotiation — not a quick capitulation. Generic entrants and market analysts should treat the undisclosed terms as potentially including licensed entry dates, suggesting the LOKELMA market may open to generic competition on a structured timeline rather than remaining permanently blocked.
ZS v Ascent — key questions answered
The case closed on 29 October 2024 via a consent judgment — a court-entered order agreed to by all parties. The case was filed on 22 August 2022 and lasted 799 days. The specific commercial terms of the consent judgment, including any market entry dates or licensing provisions, are not publicly disclosed.
Plaintiffs asserted 13 U.S. patents including US10398730B2, US11406662B2, US9592253B1, US10335432B2, US9861658B2, US10300087B2, US10413569B2, US8877255B2, US10695365B2, US9844567B2, US9913860B2, US8802152B2, and US8808750B2 — collectively covering compositions, formulations, and methods of use for sodium zirconium cyclosilicate oral suspension.
A consent judgment is a court-entered order reflecting agreement between all parties, giving it the binding force of a judicial ruling without contested merits adjudication. In ANDA litigation, it typically includes agreed findings on infringement or validity and may specify market entry dates. It is immediately enforceable and generally bars relitigation of the issues it resolves.
Hetero Drugs, Ltd. is an Indian pharmaceutical company operating as both an API manufacturer and finished-dose generic supplier. Its inclusion as a co-defendant alongside Ascent Pharmaceuticals suggests plaintiffs identified upstream supply chain exposure — specifically that Hetero may supply sodium zirconium cyclosilicate API or finished product for Ascent’s ANDA filing. This is consistent with AstraZeneca’s strategy of asserting the full patent portfolio against the entire supply chain.
LOKELMA® (sodium zirconium cyclosilicate) is a selective oral potassium binder approved for treatment of hyperkalemia, marketed by AstraZeneca. Its patent estate spans 13 asserted U.S. patents covering composition, formulation, and method-of-use claims, creating a substantial clearance burden for any ANDA filer. The consent judgment in this case reinforces the portfolio’s enforceability and signals that AstraZeneca will actively litigate to protect LOKELMA’s market exclusivity.
PatSnap Eureka searches patents and litigation data to answer instantly.